Bio-Thera Reports Results of BAT1706 (biosimilar, bevacizumab) in P-III Trial for Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Bio-Thera Reports NMPA’s Acceptance of IND for BAT2206 Proposed Biosimilar of Stelara (Ustekinumab)


  • The P-III study involves assessing of BAT1706 vs EU Avastin (bevacizumab) + chemotherapy in patients with non-squamous NSCLC, evaluating its safety, efficacy, PK & immunogenicity
  • The trial resulted in meeting its 1EPs and demonstrated the equivalence in ORR for 1L patients with advanced non-squamous NSCLC
  • BAT1706 is mAb & second biosimilar in Bio-Thera’s portfolio works as a vascular endothelial growth factor (VEGF) protein. Avastin is a mAb targeted to treat patients with metastatic colorectal cancer, non-squamous NSCLC, recurrent glioblastoma, metastatic RCC, persistent, recurrent, or metastatic CC, and epithelial ovarian, fallopian tube, or primary peritoneal cancer

Click here to read full press release/ article | Ref: Businesswire | Image: Twitter